Transforming Healthcare: Lifera and Centogene’s $30 Million Investment in Cutting-Edge Genomic

Highlights

• Lifera and Centogene work together to invest in advanced laboratory and computer technologies for analysis of biological data and offer multiomic diagnostics

• Centogene will receive a $30 million loan to fund biological and information analytic research and technology development

Lifera, a medical treatment investment firm backed by Saudi Arabia’s Public Investment Fund, has entered into a partnership with Centogene, a German biotechnology research company, aiming to advance biological and information analytic research.

The joint venture’s primary goal is to offer cutting-edge multiomic diagnostics across Saudi Arabia and the Gulf Cooperation Council (GCC) nations, catering to patients, health systems, biopharma companies, and research institutes.

As per the agreement, Lifera is extending a $30 million loan to Centogene, a NASDAQ-listed company, with a unique condition that the loan must be converted into Centogene common stock before 2024, at a conversion rate of $2.20 per share. This information was disclosed in a joint statement by Centogene and Lifera.

Kim Stratton, the Chief Executive of Centogene, expressed, “By partnering with Lifera, we are achieving a significant milestone in our mission to provide valuable information that can enhance lives globally. Together, we aim to foster sustainable growth and profitability.”

Lifera and Centogene plan to jointly invest in advanced laboratory and computer systems for understanding biological data. Centogene’s extensive database, including information from 35,000 Saudi Arabian patients, will be utilized to analyze biological data. Centogene will receive additional funding and royalties based on the joint venture’s performance until 2033.

Additionally, Centogene intends to collaborate with another entity to provide medical testing services to residents, ensuring easy access to various tests examining biological processes.

Dr Ibrahim Aljufalli, Chairman of Lifera, emphasized, “This partnership underscores Lifera’s commitment to fostering the growth of Saudi Arabia’s biopharma industry. It also facilitates global collaboration among scientists to study rare diseases in the biopharmaceutical field.”

The increased interest in pharmaceutical sector investments by government-affiliated organizations, private sector investors, and sovereign funds post the Covid-19 pandemic aligns with the goals of Vision 2030. Saudi Arabia aims to enhance its crisis management capabilities, reduce dependency on imported life-saving medications and vaccines, and boost manufacturing skills.

This joint venture, leveraging Centogene’s expertise, is poised to contribute to the success of Saudi Arabia’s health-focused programs outlined in Vision 2030.